|
18 de mayo de 2009, 11h40
|
|
IBt - International Brachytherapy s.a.: El tribunal de Charleroi nombra un nuevo presidente para el Consejo de Administración
|
|
Ibt s.a. - Seneffe, Bélgica - 15 de mayo de 2009
(Reuters: IBTH.BR - Bloomberg: IBTB BB)
La empresa ha recibido la notificación de una decisión tomada por el Presidente del Tribunal de Charleroi.
El juez, que se ha basado en una solicitud presentada por dos administradores independientes de Ibt (Jean-Pierre Delwart y Claude Onkelinx), ha decidido privar temporalmente a Andreas Eckert de su puesto de Presidente del Consejo de Administración hasta que se resuelva el caso sobre la absorción obligatoria ordenada por la CBFA (véanse anteriores notas de prensa y comunicados sobre este tema).
The Court has also decided to temporarily appoint Mr John Carden as new Chairman of the Board of IBt. Mr Carden is one of the founders of the company and has served as a Director of IBt since the incorporation of the company in 1996.
The decision of the Court is taking effect immediately.
As this decision was taken under the procedure of "extreme urgency" (hearings limited to the arguments of one party), the case will be heard on a contradictory basis in the coming days.
About IBt Bebig.
The core business of the IBt Bebig group is cancer treatment. Its specificity is the cancer treatment by the brachytherapy technique, whether achieved through permanent implants or temporary brachytherapy. The IBt Bebig group currently employs over 140 people and has entities located in Germany, France, the UK, Spain, Italy and India. The Headquarters are based in Seneffe, Belgium. The company is listed on Euronext Brussels (Reuters: IBTH.BR - Bloomberg: IBTB BB).
Contacts :
Investors Relations
Tel: +32.64.520811
E-mail: ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu
Copyright Hugin
Este anuncio fue transmitido por Hugin. El emisor es el único responsable del contenido.
[CN#153770]
|
|
|
